Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
59 hedge funds and large institutions have $33.1M invested in Adverum Biotechnologies in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 24 closing their positions.
10,843% more call options, than puts
Call options by funds: $766K | Put options by funds: $7K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.15% less ownership
Funds ownership: 5.89% → 5.75% (-0.15%)
24% less funds holding
Funds holding: 78 → 59 (-19)
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
40% less capital invested
Capital invested by funds: $55.6M → $33.1M (-$22.5M)
71% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.23M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$570K |
| 3 |
NM
Newtyn Management
New York
|
+$557K |
| 4 |
MAM
Monaco Asset Management
Monaco
|
+$330K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.31M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.35M |
| 3 |
AC
Antara Capital
New York
|
-$1.02M |
| 4 |
BlackRock
New York
|
-$610K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$528K |
ADVM Hedge Fund Activity: Q4 2022 in Review
59 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2022, worth a combined $33.1M — down 40% from $55.6M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ADVM and 7 opened new positions — a net loss of 17 holders — while 22 trimmed existing stakes and 14 added.
The largest buyer was Bank of America, adding an estimated $4.23M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $5.31M sold.
- 59 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2022, down from 78 in Q3 2022.
- Funds reported $33.1M of Adverum Biotechnologies stock for Q4 2022, down 40% quarter-over-quarter.
- 7 funds opened new Adverum Biotechnologies positions in Q4 2022 and 24 closed out, a net change of -17 holders.
- The largest Adverum Biotechnologies buyer in Q4 2022 was Bank of America, an estimated $4.23M added.
- The largest Adverum Biotechnologies seller in Q4 2022 was Soleus Capital Management, an estimated $5.31M sold.
Based on aggregated 13F filings for Q4 2022.